Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

ed for up to eight years of treatment.

About TEMSO study

TEMSO was a two-year randomized, double-blind, placebo-controlled multinational study that included 1,088 people with relapsing forms of MS from 126 centers in 21 countries. Trial participants were 18-55 years of age, with an Expanded Disability Status Scale (EDSS) of 5.5 or less, and had at least one relapse in the previous year or at least two relapses in the preceding two years. Trial participants were randomized to placebo or teriflunomide, 7mg or 14mg, once daily and followed for 108 weeks. The primary endpoint was annualized relapse rate, defined as the number of confirmed relapses per trial participant year; a relapse is a new or worsening of a previous clinical sign or symptom. The key secondary endpoint was the time to sustained disability progression, measured by the EDSS.  Disability progression was defined as an increase from baseline of at least 1.0 point on the EDSS persisting for at least 12 weeks. Change from baseline in total lesion volume was also a key prespecified MRI endpoint in the study. Safety and tolerability evaluations were based on adverse events, physical examinations, vital signs and laboratory investigations. A long-term extension of TEMSO is ongoing.

About Teriflunomide

Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation for the treatment of relapsing forms of MS. Teriflunomide blocks the proliferation and functioning of activated T and B lymphocytes - which are thought to be especially damaging in MS - by selectively and reversibly inhibiting a critical mitochondrial enzyme. With nine years of continuous use in a Phase II extension, teriflunomide has the longest clinical experience of any investigational oral MS therapy. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in people with RMS. A Phase III study, TOPIC, is also underway
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  David Hardison, Ph.D., vice president of ... has been elected chairman of the board for ... working to establish common protocols around the use ... to electronic health records. Hardison ... with organizations across the research and health care ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2
... 12 Eurand N.V.,(Nasdaq: EURX ), a ... products based on its proprietary drug,formulation technologies, announced ... in the NASDAQ Biotechnology Index (Nasdaq: NBI ... Executive Officer of Eurand, commented, "We are,delighted to ...
... Pa., Nov. 9 ,Southern Research Institute and ... expanded their joint marketing agreement to allow ... biotechnology and,pharmaceutical markets. Ten months ago, the ... joint marketing agreement to collaborate in,marketing contract ...
... tests at once with minimal patient discomfort, ... announced today the launch of the ComforTen(TM) Multiple ... device features ten,surgical steel 1.2mm lancet tips, which ... is the only 10-test, self-loading,surgical steel testing device ...
Cached Biology Technology:Eurand Added to NASDAQ Biotechnology Index 2Eurand Added to NASDAQ Biotechnology Index 3Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3
(Date:7/28/2014)... that have seen an increase in so-called "nuisance flooding"--which ... storm drains and compromised infrastructure--are on the East Coast, ... nuisance flooding, caused by rising sea levels, has increased ... percent since the 1960s. , The report, Sea Level ... States, also finds Annapolis and Baltimore, Maryland, lead the ...
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3How sweet it is 2How sweet it is 3
... Catch an athlete with clear potential early in his ... years including victory in the Tour de France, and ... about what training and dedication can accomplish. , What ... out about Lance Armstrong was that from 1992-1999, the ...
... vaccines for related viruses including dengue fever. A monoclonal ... Nile virus has an intriguing secret: Contrary to scientists' ... attach to host cells. Instead, the antibody somehow stops ... "This was a complete surprise to us, but it ...
... at the University of Florida's McKnight Brain Institute have ... first time duplicates neurogenesis -- the process of generating ... in today's (June 13) Proceedings of the National Academy ... holds the promise of producing a limitless supply of ...
Cached Biology News:Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 2Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 3Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 4Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 5Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 6Secrets to antibody's success against West Nile Virus surprise scientists 2Secrets to antibody's success against West Nile Virus surprise scientists 3Secrets to antibody's success against West Nile Virus surprise scientists 4For first time, brain cells generated in a dish 2For first time, brain cells generated in a dish 3
Lysozyme C (W-20)...
... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
... (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a chromogenic ... recombinant plasmids. In the ... IPTG, lac + ... whereas recombinant colonies appear ...
... enhanced form of Tobacco Etch Virus (TEV) ... and significantly more stable than native TEV ... specifically recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, ... useful for removing affinity tags from fusion ...
Biology Products: